 The first cohort will be administered 0.2mg. Administration of AEF0117 to the subsequent dose cohorts,0.6 mgCohort II, 2 mg Cohort III, and 6 mg Cohort IV doses should not occur before participants in the previous dose cohort have been treated and data i.e. safety results from those participants are reviewed in accordance with the protocol. 